Kurve Technology, Inc., a leader in nasal drug delivery devices, today announced industry thought leader Dr. Sveinbjörn Gizurarson has joined the Company’s Scientific Advisory Board as a member.
BOTHELL, WA (PRWEB) June 29, 2006 -- Kurve Technology, Inc., a leader in nasal drug delivery devices, today announced industry thought leader Dr. Sveinbjörn Gizurarson has joined the Company’s Scientific Advisory Board as a member.
Dr. Gizurarson has extensive research and business experience in the development of nasal drug and vaccine delivery systems. In 1991, Dr. Gizurarson founded Lyfjathroun Biopharmaceuticals, a nasal drug delivery company that initially focused on the safe and non-invasive nasal delivery of antigens and currently specializes on the delivery of rapid-onset nasal products. Dr. Gizurarson served as Lyfjathroun’s CEO between 1999 and 2005.
Dr. Gizurarson’s research is widely published, and he has served on journal editorial boards as well as on international government and academic bodies handling issues related to life sciences. Currently a Professor of Pharmacy and Clinical Therapeutics at the University of Iceland, Dr. Gizurarson has served on the faculty since 1991 after receiving his Ph.D. from The Danish University of Pharmaceutical Sciences.
"We are honored by Dr. Gizurarson's decision to to help Kurve Technology as we strive to be a market leader in nasal drug delivery products. His expertise and experience will contribute enormously to our product development and clinical programs," said Marc Giroux, CEO of Kurve Technology.
"Kurve Technology is working hard on developing truly innovative nasal drug delivery device technologies,” said Dr. Gizurarson. “There is a major unmet medical need in the nasal delivery space and I look forward to being able to contribute to Kurve Technology’s exciting research and development efforts."
About Kurve Technology, Inc.
Kurve Technology, Inc. offers pharmaceutical companies innovative nasal delivery systems for local, systemic and nose-to-brain medical therapies. Kurve’s Controlled Particle Dispersion (CPD)™ technology intranasally delivers formulations with far greater efficacy and efficiency than traditional methods. The ViaNase™ product line of intelligent atomizers delivers a wide range of compounds, aiding the more than 200 million patients who suffer from such medical conditions as allergic rhinitis, chronic rhinosinusitis, sexual dysfunction, migraine headache, obesity, and central nervous system (CNS) diseases. Kurve Technology is headquartered in Bothell, WA with an office in Research Triangle Park, NC. For additional information, please visit www.kurvetech.com.
###
Trackback URL: http://www.prweb.com/pingpr.php/U3VtbS1Mb3ZlLUNyYXMtQ291cC1JbnNlLVplcm8=
|
